News Headlines Article

Blood cancer startup targets treatment personalization
San Francisco Business Times

Matt De Silva was working at Peter Thiel’s hedge fund, Clarium Capital, when he learned his father had three rare brain tumors. That discovery led De Silva to a deep dive into personalized cancer drug recommendations — and ultimately toward founding Notable Labs.

The Foster City-based company pairs artificial intelligence software with flow cytometry lab instruments to figure out which treatment, or combination of drugs, will be the most effective for different types of cancers. Notable is focused on blood cancers, such as leukemia, because of the large amount of cells available for testing and the quicker turnaround time, De Silva said. In turn, the company is looking to assist drug companies and academic institutions in recruiting the right kinds of patients for clinical trials.